Untargeted Metabolome Atlas for Sleep Phenotypes in the Hispanic Community Health Study/Study of Latinos

- Ying Zhang¹, Brian W Spitzer², Yu Zhang², Danielle A Wallace^{1,2,3}, Bing Yu⁴, Qibin Qi⁵, Maria
 Argos^{6,7}, M Larissa Avilés-Santa⁸, Eric Boerwinkle⁴, Martha L Daviglus⁹, Robert Kaplan^{5,10},
 - Jianwen Cai¹¹, Susan Redline^{1,3}, Tamar Sofer^{1,2,3,12,*}
- 7 ¹Division of Sleep Medicine and Circadian Disorders, Department of Medicine, Brigham and Women's
- 8 Hospital, Boston, MA, USA
- 9 ²CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
- 10 ³Department of Medicine, Harvard Medical School, Boston, MA, USA
- ⁴Department of Epidemiology, School of Public Health, The University of Texas Health Science Center at
- 12 Houston, Houston, TX, USA
- ⁵Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New
 York, USA
- ⁶Department of Epidemiology and Biostatistics, School of Public Health, University of Illinois Chicago,
- 16 Chicago, IL, USA
- 17 ⁷Department of Environmental Health, School of Public Health, Boston University, Boston, MA, USA
- ⁸Division of Clinical and Health Services Research, National Institute on Minority Health and Health
 Disparities, National Institutes of Health, Bethesda, MD, USA
- ⁹Institute for Minority Health Research, University of Illinois at Chicago, Chicago, IL, USA
- ¹⁰Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA
- 22 ¹¹Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at
- 23 Chapel Hill, Chapel Hill, NC 27599, USA
- 24 ¹²Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
- 25

3

6

- 26
- 27 *Correspondence:
- 28 Tamar Sofer
- 29 Center for Life Sciences, CLS-934
- 30 3 Blackfan St
- 31 Boston, MA, 02116
- 32 tsofer@bidmc.harvard.edu
- 33

- 35
- 36
- 37
- 38
- 38 39

40

41 Abstract

42 Sleep is essential to maintaining health and wellbeing of individuals, influencing a variety of outcomes from mental health to cardiometabolic disease. This study aims to assess the relationships between 43 44 various sleep phenotypes and blood metabolites. Utilizing data from the Hispanic Community Health 45 Study/Study of Latinos, we performed association analyses between 40 sleep phenotypes, grouped in 46 several domains (i.e., sleep disordered breathing (SDB), sleep duration, timing, insomnia symptoms, and 47 heart rate during sleep), and 768 metabolites measured via untargeted metabolomics profiling. Network 48 analysis was employed to visualize and interpret the associations between sleep phenotypes and 49 metabolites. The patterns of statistically significant associations between sleep phenotypes and 50 metabolites differed by superpathways, and highlighted subpathways of interest for future studies. For example, some xenobiotic metabolites were associated with sleep duration and heart rate phenotypes 51 52 (e.g. 1H-indole-7-acetic acid, 4-allylphenol sulfate), while ketone bodies and fatty acid metabolism metabolites were associated with sleep timing measures (e.g. 3-hydroxybutyrate (BHBA), 3-53 54 hydroxyhexanoylcarnitine (1)). Heart rate phenotypes had the overall largest number of detected 55 metabolite associations. Many of these associations were shared with both SDB and with sleep timing 56 phenotypes, while SDB phenotypes shared relatively few metabolite associations with sleep duration 57 measures. A number of metabolites were associated with multiple sleep phenotypes, from a few 58 domains. The amino acids vanillylmandelate (VMA) and 1-carboxyethylisoleucine were associated with 59 the greatest number of sleep phenotypes, from all domains other than insomnia. This atlas of sleep-60 metabolite associations will facilitate hypothesis generation and further study of the metabolic underpinnings of sleep health. 61

62

63 Introduction

64	Sleep plays an important role in the health and wellbeing of individuals. Insufficient quality, timing, and
65	duration of sleep have a major public health impact, and are associated with daytime sleepiness, poor
66	mental health, impaired cognitive function, and increased risk of cardiovascular morbidity and mortality
67	(1–3). Sleep is increasingly recognized as a crucial factor in cardiovascular health, evident by the addition
68	of sleep duration to the "life's essential 8" metric developed by the American Heart Association(4). In
69	addition to sleep duration, measures of suboptimal sleep, such sleep disturbances and quality (or
70	insomnia symptoms), irregularity of sleep timing, sleep fragmentation, and sleep disordered breathing
71	(SDB), are also associated with poor health outcomes (5). In fact, there is growing recognition of the
72	importance in measuring and characterizing multi-dimensional sleep health— a framework that
73	concurrently considers these varied aspects of sleep (6–8).

74

Despite the strong epidemiological evidence observed in many cohort and clinical studies for the connection between suboptimal sleep health and increased risks for poor health outcomes, the biology and physiology behind these links are not fully understood. While many sleep behaviors and outcomes share some underlying genetic and physiological pathways (9–11), or have, potentially bidirectional, causal relationships (12), there may also be distinct mechanisms that underlie specific sleep disturbances or sleep subtypes (13–15). Untangling these shared and distinct mechanisms underlying sleep phenotypes has the potential to inform sleep health intervention efforts.

83 Biological sampling to measure molecular markers of health, such as in metabolomics, can be used to 84 investigate the mechanisms and pathways underpinning sleep phenotypes. Metabolites are small 85 molecules produced in the formation and/or breakdown of endogenous or exogenous substances and 86 are oriented at the closest layer to phenotypes compared to other underlying biochemical layers (e.g., 87 genome, transcriptome and proteome). The increasing availability of large datasets with untargeted 88 metabolomics profiling has unveiled metabolic outcomes and correlates of numerous health 89 phenotypes, including sleep measures (16–31). A large-scale study of metabolites in relation to sleep 90 phenotypes may shed light on how underlying biological processes may converge and differ among 91 common sleep phenotypes, the complex interplay between sleep and the metabolic environment, and, 92 ultimately, potential interactions among sleep disorders and progression of cardiometabolic and other 93 health conditions. Here, we study the associations between a range of sleep phenotypes and the 94 metabolic environment in a large population-based study using a high-dimensional set of measured 95 metabolites. We create an "atlas" – a resource for the sleep research community that will facilitate 96 hypotheses formulation and accelerate studies on sleep and its association with other health outcomes.

97

98 Our study has taken a comprehensive approach, covering key sleep phenotypes including sleep 99 disordered breathing (SDB), sleep duration, sleep timing, insomnia symptoms, and heart rate (HR) 100 during sleep. Each category of sleep phenotypes provides a different perspective on sleep, while 101 together may highlight some shared biological processes within this complex physiological 102 phenomenon. We also conducted network analysis to better understand the interconnectedness 103 between multiple sleep phenotypes and metabolites –representing significant associations as links in a 104 bipartite network allows for simultaneous visualization of many associations, enabling researchers to 105 perceive connectivity patterns that might otherwise be obscured when looking at the individual 106 relationships. By reporting a large number of associations between metabolites and sleep phenotypes,

107	this resource may provide researchers with a starting point for more targeted inquiries into the
108	metabolic environment changes induced by sleep disorders, and facilitate hypothesis generation for
109	future metabolomic sleep research. This may ultimately contribute to our understanding of the
110	pathogenesis of sleep disorders and pave the way for developing more effective diagnostic and
111	therapeutic strategies.
112	
113	Methods
114	The Hispanic Community Health Study/Study of Latinos
115	The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a prospective community-based
116	cohort study of 16,415 Hispanic/Latino individuals aged 18–74 years at the baseline examination (2008-
117	2011). Study participants were selected using a multi-stage stratified random sampling from four
118	geographic regions: Bronx NY, Chicago IL, Miami FL, and San Diego CA (32,33). Description of major
119	ancillary studies and findings in the context of cardiovascular health is provided in a prior publication
120	(34). Fasting blood samples were collected at the baseline examination, and within the subsequent
121	week, 14,440 of these participants underwent an evaluation for SDB using a validated Type 3 home
122	sleep apnea test (ARES Unicorder 5.2; B-Alert, Carlsbad, CA) that measured nasal airflow, position,
123	snoring, heart rate and oxyhemoglobin saturation with measures of SDB scored by a central reading
124	center as detailed previously (35). All sleep phenotypes used and their definitions are provided in
125	Supplementary Note 1.

127 Metabolomics profiling

128	From those who attended the HCHS/SOL baseline assessment and also underwent genotyping (12,803
129	of the study individuals (36)), 4,002 individuals were selected at random for metabolomics profiling of
130	fasting serum samples collected at baseline (metabolomics batch 1, processed in 2017). In 2021,
131	additional 2,368 serum samples from 2,330 participants, also collected at baseline, were profiled in a
132	second metabolomics batch 2. Serum samples were stored at -70°C at the HCHS/SOL Core Laboratory at
133	the University of Minnesota until analysis by Metabolon, Inc. (Durham, NC) in 2017 (batch 1) and 2021
134	(batch 2). Serum samples were then extracted and prepared using Metabolon's standard solvent
135	extraction method. Extracts were split into a five fractions to use in four liquid chromatography-mass
136	spectrometry (LC-MS)-based metabolomic quantification platforms (two reverse phase methods with
137	positive ion mode electrospray ionization (EI), one reverse phase method with negative ion mode EI, and
138	one hydrophilic interaction liquid chromatography with negative ion mode EI), with the fifth fraction
139	reserved for backup. Instrument variability was assessed by calculating the median relative standard
140	deviation (SD) for the internal standards added to each sample prior to injection into the mass
141	spectrometers. Overall process variability was determined by calculating the median relative SD for all
142	endogenous metabolites (i.e., non-instrument standards) present in 100% of the technical replicate
143	samples.

144

145 Metabolomic data pre-processing

Preprocessing of the metabolomic data is described in Supplementary Figure S1. First, we removed batch 2 individuals who overlapped with batch 1 and replicate samples from the same individuals, resulting in 2,178 remaining batch 2 observations. We then computed percentages of missing values of each metabolite in each batch separately. We excluded metabolites with missing values in more than

150 75% of the individuals in either batch. For xenobiotic metabolites (metabolite annotation was provide by 151 Metabolon), we assumed that missing values were due to concentrations below the minimum detection 152 limits, thus imputed the missing values for each metabolite with half of the lowest non-missing value of 153 that metabolite across the sample within the batch. For non-xenobiotic metabolites, we applied multiple 154 imputation using the futuremice function from the R mice package (version 3.15.0) that implements 155 fully conditional imputation in a computationally efficient manner (using parallelization). Each variable 156 in the imputation dataset is imputed (if it has missing values) using a model that predicts potential 157 values based on other variables in the dataset. The dataset was imputed 5 times to generate 5 158 completed datasets. Differences between the computed datasets are due to randomness (e.g. random 159 residuals added to the predicted values of a variable). We imputed metabolites, separately in each 160 batch, together with a set of covariates that are strongly linked to the metabolic environment: age, sex, 161 BMI, waist-to-hip ratio, fasting insulin, fasting glucose, type 2 diabetes status (American Diabetes 162 Association definition: fasting glucose >=126 mg/dL, or post-OGTT glucose >=200 mg/dL or A1C>=6.5%, 163 or self-report of diabetes), estimated glomerular filtration rate, and lipid measures - total cholesterol, 164 triglycerides, high- and low-density lipoprotein measures. We then rank normalized the 768 metabolite 165 measures passing quality control in each batch separately and each imputed dataset separately, and 166 finally, aggregated data from the two batches, such that the "first" imputed batch 1 dataset was 167 aggregated with the "first" imputed batch 2 dataset, and so on. Supplementary Note 2 describes the 168 analysis we performed to inform the metabolite imputation strategy.

169

170 Sleep phenotypes and modeling approach

171 We used 40 sleep phenotypes from 5 domains, described in detail in Supplementary Note 1. In brief,

these included: self-reported sleep duration (sleep duration during weekdays and weekend days,

173 average sleep duration during, short and long sleep during weekdays), heart rate during sleep 174 (minimum, maximum, average, and standard deviation of HR), insomnia (the women health initiative 175 insomnia rating scale (WHIRS), its component questions, sleeping pill use, and daytime and excessive 176 daytime sleepiness, measured via the Epworth sleepiness scale), sleep disordered breathing (respiratory 177 event indices, measures of oxyhemoglobin saturation during sleep, measures of respiratory event 178 lengths, as well as self-reported snoring), and sleep timing (bed time and wake time as well as sleep 179 midpoint during weekend and weekend days, and social jetlag – the difference in sleep midpoint 180 between weekend and weekdays). In figures and tables, these domains are referred to as Duration, HR, 181 Insomnia, SDB, and Timing. Phenotypes in the sleep timing category were analyzed as "circular" 182 variables, i.e., to avoid bias due to day thresholding (i.e., defining a day by midnight) and to account for 183 the fact that 11:59PM (23:59) is adjacent to 12:01AM (00:01). Other sleep phenotypes were treated as 184 linear or binary (when dichotomized). Two nested conceptual models were used in the analyses. Model 185 1 adjusted for batch number, demographic, and baseline clinical variables, including age, sex, field 186 center, Hispanic/Latino background (Mexican, Puerto Rican, Cuban, Central American, Dominican, South 187 American, and other/multi) and body mass index (BMI). Model 2 further adjusted for lifestyle variables – 188 alcohol use (never, former, current), cigarette use (never, former, current), total physical activity (MET-189 min/day, computed based on self-reported time spent doing physical activities), and diet (Alternative 190 Healthy Eating Index 2010, computed based on 24 hours dietary recall data) in addition to Model 1 191 covariates. Sleep phenotypes were used as exposures with metabolites as outcomes. When testing the 192 association of a circular phenotype (i.e., sleep timing) with a metabolite, we first converted the sleep 193 timing phenotype into radians (with 12am serving as the 0) and then computed the sine and cosine of 194 these radians. We used the sine and cosine terms as predictors in the regression (37), and tested their 195 association with the metabolite using the multivariate Wald test, accounting for two predictors and their 196 estimated covariance. All association analyses were performed using the survey R package (version 4.1)

to account for the HCHS/SOL sampling design and provide effect estimates relevant for the HCHS/SOL
 target population.

199

200 Estimating associations between metabolites and sleep phenotypes

201 We separately assessed the association between each metabolite's concentration level, as an outcome, 202 and each sleep phenotype, as a predictor, using Model 1 and Model 2 covariates as described above, in 203 a single metabolite association analysis. Xenobiotic metabolites were imputed once, while missing 204 values in other metabolites values were imputed 5 times. Thus, we estimated the associations of non-205 xenobiotic metabolites with sleep phenotypes 5 times (using each of the completed datasets), and then 206 combined the resulting estimated associations. Here we treated the linearly-modeled sleep phenotypes 207 differently from the circular ones. The estimated metabolite associations with linearly-modeled sleep 208 phenotypes were combined using Rubin's rule (38). Sleep timing phenotypes cannot be combined in the 209 same manner, because there is no method to combine the covariance between the sine and cosine 210 terms across several completed datasets. Instead, we focused on testing and aggregated the p-value of 211 the multivariate Wald test using the aggregated Cauchy association test (ACAT; (39)). The ACAT test was 212 developed in the context of genetic association analyses, but it is appropriate for our settings, because it 213 allows for the aggregated tests to be based on correlated data. Finally, after combining association 214 results so we had one p-value per sleep phenotype-metabolite association (per model), we 215 implemented the Benjamini-Hochberg method to control the false discovery rate (FDR) for multiple 216 testing across all metabolites in all models for each sleep phenotype (40). Any association that resulted 217 in an FDR-adjusted p-value<0.05 in Model 1 was considered statistically significant. In secondary 218 analysis, we also performed sex-stratified analyses using the same analytic approach. For descriptive 219 purposes, we computed the number of sleep traits that each metabolite was associated with at the

FDR<0.05 Model 1 threshold, and identified the top 10% metabolites based on number of sleep traitassociations.

222

We summarized the associations between sleep phenotypes, individually and categorized by domains, and metabolites, individually and categorized by pathways. Similarities of these associations between a pair of phenotypes or domains were estimated with the Dice Similarity Coefficient (DSC) (41) defined as

$$DSC = \frac{2|X \cap Y|}{|X| + |Y|}$$

Where *X* and *Y* represent the set of metabolites with statistically significant associations (FDR<0.05) with two sleep phenotypes or domains. DSC takes values between 0 and 1 where 0 indicates no similarity while 1 indicates full overlap between the two sets.

230

231 Bipartite network analysis

232 Bipartite network is a type of network in which there are two groups of nodes (here: sleep phenotypes 233 and metabolites), and links, or edges, can only exist between the two types of nodes but not within a 234 group of nodes. We constructed a bipartite network using the sleep phenotypes and metabolites, where 235 an edge was added between a sleep phenotype-metabolite pair if their association was statistically 236 significant (FDR-adjusted p-value<0.05) in Model 1 association analysis. The network is built based on an 237 incidence matrix, with rows corresponding to sleep phenotypes, columns represent metabolites, and the 238 *i*, *j* cell in this matrix has a value of 1 if the *i*th sleep phenotype has a statistically significant association 239 with the *j*th metabolite, and 0 otherwise. We then aggregated metabolites by sub- and super-pathway, 240 and sleep phenotypes by domain, which results in a consolidated incidence matrix in which a value of 1 241 in cell(*m*,*n*) indicating any statistically significant association between the *m*th sleep phenotype domain

242	and the <i>n</i> th metabolite sub- and super-pathway and a weight matrix documenting the number of total
243	statistically significant associations between the <i>m</i> th sleep phenotype domain and the <i>n</i> th metabolite
244	sub- and super-pathway. Several network property metrics were computed to offer insights into the
245	structure and associations of the sleep domain – metabolite sub- and super- pathway network.
246	
247	For visualization, we converted the bipartite network into a univariate network and visualized the
248	network using the Fruchterman-Reingold force-directed algorithm, which optimizes the placement of
249	nodes based on connectivity similarity between nodes, where similar connectivity is reflected as
250	proximity of nodes (42), providing an intuitive spatial representation of the network structure.
251	
252 253	Statistical software
254	All analyses were done in R version 4.2.3. The function svyglm from the survey package was used for
255	survey-weighted generalized linear regression models. The car package (version 3.1) was used for
256	multivariate Wald test. The bipartite package (version 2.18) was used for bipartite network analysis, and
257	igraph (version 1.5) and ggnetwork (version 0.5) packages were used for visualizing network graph.
258	
259 260	Results
261	Study sample characteristics
262	Table 1 characterizes the HCHS/SOL target population (using means and percentages weighted to
263	account for study participation), with more comprehensive data provided in Supplementary Table S1.
264	The analytic sample, batch 1 and batch 2 metabolomic dataset combined, included 6,180 participants

- with a mean age of 44.31 years (SD=15.27), of whom 40.1% were males, 20.7% were non-alcohol users,
- 266 58.5% never smoked, and 11.7% had moderate-to-severe OSA (REI3>=15). The average sleep duration
- 267 was 7.98 hours (SD=1.46), while 22.7% reported restless or very restless sleep on a typical night in the
- last month, and 15.8% reported excessive sleepiness (ESS>=10). Batch 2 participants were older
- compared to batch 1 the mean age is 41.54 years (SD) in batch 1 and 51.11 years (SD) in batch 2. The
- 270 baseline rates of diabetes and hypertension were higher in batch 2 (diabetes: 29.4%; hypertensions:
- 44.1%) compared to batch 1 (diabetes: 20.1%; hypertensions: 31.5%), consistent with the age difference
- 272 between the two batches.

Table 1: HCHS/SOL target population characteristics by sex, batch, and overall					
	Female	Male	Batch 1	Batch 2	Overall
n	3704	2476	4002	2178	6180
Age (mean (SD))	44.98	43.56 (15.35)	41.54	51.11	44.31
	(15.17)		(15.18)	(13.21)	(15.27)
Gender = Male (%)	0 (0.0)	2476 (100.0)	1705	771	2476
			(42.6)	(35.4)	(40.1)
Hispanic/Latino background (%)					
BMI (mean (SD))	30.15	28.78 (5.37)	29.42	29.72	29.50
	(6.69)		(6.27)	(5.80)	(6.14)
Current alcohol drinking (%)	1401	1490 (60.2)	1973	918	2891
	(37.9)		(49.3)	(42.3)	(46.8)
Current smoking (%)	596	668 (27.1)	863	401	1264
	(16.1)		(21.6)	(18.5)	(20.5)
Physical activity (MET-min/day) (mean (SD))	424.88	879.70	697.66	496.61	639.60
	(714.71)	(1174.88)	(1020.41)	(880.66)	(986.25)
The Alternate Healthy Eating Index (2010) (mean (SD))	46.79	48.74 (7.47)	47.28	48.75	47.71
	(7.42)		(7.52)	(7.36)	(7.50)
OSA status = OSA (%)	260 (383 (17.4)	388	255	643
	7.9)		(10.9)	(13.0)	(11.7)
Baseline Diabetes status (ADA) = Yes (%)	863	579 (23.4)	803	639	1442
	(23.3)		(20.1)	(29.4)	(23.3)
Baseline Hypertension status = Yes (%)	1357	865 (34.9)	1261	961	2222
	(36.6)		(31.5)	(44.1)	(36.0)
Sleep Duration: Work/School Days (in hours) (mean (SD))	7.89	7.75 (1.56)	7.82	7.83	7.82
	(1.66)		(1.62)	(1.60)	(1.62)
Womens's Health Initiative Insomnia Rating Scale (WHIIRS)	7.64	6.16 (5.13)	6.78	7.34	6.95
total score (mean (SD))	(5.58)		(5.37)	(5.54)	(5.42)
Epworth Sleepiness Scale (ESS) total score (mean (SD))	5.44	5.87 (4.87)	5.62	5.70	5.64
	(4.71)		(4.71)	(4.99)	(4.79)
OSA was defined as respiratory event index >=15.					
Means and percentages have been weighted to provide values representative of the HCHS/SOL target population.					

275 Results from sleep phenotype-metabolite association analysis

276	The single metabolite association analysis was conducted in pair-wise fashion between 40 sleep
277	phenotypes from five domains (i.e., sleep duration, HR during sleep, insomnia, SDB, and sleep timing)
278	and 768 metabolites, including 113 unknown metabolites and 77 xenobiotic metabolites. Of the
279	phenotypes, 35 sleep phenotypes had statistically significant associations with at least one metabolite
280	(Table 2). When limited to Model 1, the median number of significant associations for each sleep
281	phenotype is 16.5 (range: 0 - 304), corresponding to 2.15% (range: 0% – 39.58%) of all tested
282	metabolites. The number of statistically significant associations is much lower among dichotomized
283	sleep phenotypes (median: 5; range: 0 – 73) compared to non-dichotomized sleep phenotypes (median:
284	37; range: 0 – 304), likely corresponding to loss of power due to dichotomization. Phenotypes from the
285	heart rate during sleep domain had the highest number of statistically significant associations with
286	metabolites (median: 174, range: 2 - 304), followed by the sleep timing domain (median: 117, range: 64
287	- 197). The SDB domain had the lowest number of statistically significant associations with tested
288	metabolites (median: 8, range: 0 – 68) (Supplementary Table S2). Figure 2 visualizes the strength of
289	associations (i.e., negative logarithm of the FDR-adjusted p) between sleep phenotypes and individual
290	metabolites grouped by superpathway. Compared to the sex-stratified analysis, sex-combined analysis
291	tends to identify more statistically significant associations between sleep phenotypes and metabolites
292	(Figure 3), in accordance with the higher power due to larger sample size of the sex-combined analysis.

293

Table 2: Statistically significant metabolite associations by sleep phenotype				
Sleep phenotype	Number of statistically significant	Percentage of statistically significant	Sleep phenotype domain	Sleep phenotype dichotomized or continuous
weekday long sleen	associations	associations (%)	Duration	Dichotomized
weekday long sleep	2	0.20	Duration	Dichotomized
sleen duration	107	13.93	Duration	Continuous
weekday sleen duration	107	13.55	Duration	Continuous
social intlag	0	0.00	Duration	Continuous
weekend sleen Duration	3	0.00	Duration	Continuous
min HR during sleen	225	29.30	Heart rate (HR)	Continuous
max HR during sleep	123	16.02	Heart rate (HR)	Continuous
avg HR during sleen	304	39.58	Heart rate (HR)	Continuous
std HR during sleep	2	0.26	Heart rate (HR)	Continuous
difficulty back to sleep	0	0.00	Insomnia	Dichotomized
early wake	16	2.08	Insomnia	Dichotomized
ESS	34	4.43	Insomnia	Continuous
ESS>10 (EDS)	8	1.04	Insomnia	Dichotomized
difficulty fall asleep	17	2.21	Insomnia	Dichotomized
frequent wake	0	0.00	Insomnia	Dichotomized
taking sleep pill	73	9.51	Insomnia	Dichotomized
restless sleep	6	0.78	Insomnia	Dichotomized
WHIIRS	35	4.56	Insomnia	Continuous
avg event Duration	0	0.00	SDB	Continuous
hypoxic burden	7	0.91	SDB	Continuous
per90	1	0.13	SDB	Dichotomized
rei0	11	1.43	SDB	Continuous
rei0>15	4	0.52	SDB	Dichotomized
rei0>5	27	3.52	SDB	Dichotomized
total event count	12	1.56	SDB	Continuous
total event Duration	7	0.91	SDB	Continuous
rei3	68	8.85	SDB	Continuous
rei3>15	8	1.04	SDB	Dichotomized
rei3>5	43	5.60	SDB	Dichotomized
min o2	38	4.95	SDB	Continuous
avg o2	36	4.69	SDB	Continuous
perlt90	8	1.04	SDB	Continuous
snore	4	0.52	SDB	Dichotomized
weekday bed time	158	20.57	Timing	Continuous
weekday midpoint time	197	25.65	Timing	Continuous
weekday wake time	153	19.92	Timing	Continuous

weekend bed time	80	10.42	Timing	Continuous
weekend midpoint time	81	10.55	Timing	Continuous
weekend wake time	64	8.33	Timing	Continuous

296	Among the 768 included metabolites, carbohydrates had the highest average number of statistically
297	significant associations with sleep phenotypes (mean: 4.23, range: $1-8$ per metabolite), followed by
298	cofactors and vitamins (mean: 3.92, range $0-12$ per metabolite) and lipids (mean: 3.04, range: $0-11$
299	per metabolite). Partially characterized molecules (mean: 1.78, range: $0-8$) and xenobiotics (mean:
300	1.78, range: $0-9$) had the lowest number of statistically significant associations with sleep phenotypes
301	per metabolite (Supplementary Table S3).
302	
303	We aggregated metabolites by subpathway and sleep phenotypes by domain, then identified and
304	visualized top metabolomic subpathways with over 25% statistically significant associations (defined as
305	FDR-adjusted <i>p</i> <0.05) among all tested associations (Figure 4) by sleep phenotype domain. Primary bile
306	acid metabolism showed the highest cumulative percentage of statistically significant associations
307	across all five sleep phenotype domains, although no significant association was identified for SDB
308	phenotypes (Supplementary Table S4). Both lipids and cofactors/vitamins had subpathways (e.g., ketone
309	bodies, acyl glutamine, pantothenate and CoA metabolism, nicotinate and nicotinamide metabolism)
310	that had high percentage of statistically significant associations with sleep timing phenotypes. SDB
311	phenotypes had the highest percentage of statistically significant associations among lipids, especially
312	progestin steroids, phosphatidylethanolamine, diacylglycerols, pregnenolone steroids and
313	sphingomyelins, which is consistent with our previous research findings (43). As for the sleep duration
314	domain, the top subpathways with the highest percentage of significant associations were
315	bacterial/fungal, amino sugar metabolism, nicotinate and nicotinamide metabolism, primary bile acid

- 316 metabolism, corticosteroids, and polyamine metabolism. Insomnia domain generally had fewer
- 317 statistically significant associations, among which pregnenolone steroids and vitamin A metabolism
- 318 showed the highest percentage of statistically significant associations.

319

- 320 Comparing men and women, potential sex differences can be observed (Supplementary Figure S2), with
- 321 the limitation that the sample size of male participants was lower. Relatively more subpathways had
- 322 statistically significant associations with SDB phenotypes among females compared to males (these
- include oxidative phosphorylation, lactosylceramides fructose, mannose and galactose metabolism). The
- 324 subpathways from which metabolites were associated with insomnia phenotypes were mostly
- 325 pregnenolone steroids, nicotinate and nicotinamide metabolism and carnitine metabolism among
- 326 females, while long chain saturated and monounsaturated fatty acid and amino sugar metabolism were
- 327 more associated with insomnia phenotypes among males.

328

329 We also aggregated metabolites by superpathway and visualized the percentage of statistically

330 significant associations between superpathways and sleep phenotype domains in the format of a

- heatmap (Figure 5). The percentage of statistically significant associations were highest for HR during
- 332 sleep, especially among carbohydrates (40.34%), followed by cofactors and vitamins (26.92%), amino
- acids (24.70%) and peptides (24.04%) (Supplementary Table S5). Insomnia and SDB domain showed
- 334 overall lower percentage of statistically significant associations with metabolites across all

superpathways, all of which were below 10%.

337 Among all metabolites associated with at least one sleep phenotype, we identified the top 10% (n=37) 338 with the highest number of total associations, regardless of domains (Figure 6). Sixteen metabolites 339 were lipids, 8 were amino acids, 4 were cofactors and vitamins, 4 were unnamed, 2 were peptides, 1 340 was carbohydrate, 1 was xenobiotic and 1 was partially characterized. Every metabolite from the top 341 10% list had associations with more than one sleep phenotype domain, among which 11 metabolites 342 were associated with four different domains of sleep phenotypes. The amino acids Vanillylmandelate 343 (VMA) and 1-carboxyethylisoleucine were associated with the greatest number of sleep phenotypes 344 from all sleep phenotype domains except for the insomnia domain.

345

We also compared the similarities among sleep phenotype domains by calculating the Dice Similarity Coefficients (DSC) which quantifies the associated metabolites overlap between any two sleep domains. As shown in Figure 7, the highest overlap was observed between HR during sleep phenotypes and SDB (DSC=0.35), and with sleep timing domain (DSC=0.35), respectively. The overlap between SDB and sleep timing domain was lower (DSC=0.26). High overlap was also observed between sleep duration and sleep timing (DSC=0.31). The lowest levels of overlap were observed for sleep duration traits and SDB domain (DSC=0.13) and sleep duration and HR during sleep phenotypes (DSC=0.19).

353

Bipartite network analysis based on statistically significant associations betweenmetabolites and sleep phenotypes

Figure 8 shows a network of nodes and edges in which each node represents either a sleep phenotype domain or a metabolomic subpathway, while each edge represents one or more statistically significant associations between two nodes based on the single metabolite association analysis results (FDRadjusted p<0.05). The width of the edge indicates the number of statistically significant associations between two nodes. Some metabolomic subpathways have exclusive connections with one sleep

361 domain, such as fatty acid and dicarboxylate subpathways and sleep timing domain. Others tend to have 362 many connections with multiple sleep domains, such as sphingomyelins with sleep timing, heart rate 363 and SDB phenotype domain. The placement of the nodes reflects their connectivity similarities – the 364 closer two nodes are, the more similar their overall connectivity patterns are. SDB and heart rate 365 phetnoypes, for instance, are closely placed together which also corresponds to the high DSC values 366 between the two groups (Figure 7). Metabolomic subpathways located close to the center of the 367 network indicates their connectivity with multiple sleep domains, while metabolomic subpathways 368 located at the outskirt of the network indicates their connections with one or few closely located sleep 369 phenotype domains. For instance, the cluster of fatty acids (i.e., fatty acid, dicarboxylate, fatty acid 370 metabolism (acyl carnitine, hydroxy), fatty acid metabolism (acyl choline), long chain saturated fatty 371 acid, and fatty acid, monohydroxy, appearing in the left guadrant of Figure 8) are mostly connected to 372 sleep timing, heart rate, and insomnia sleep domains, while lipids such as lysophospholipid, secondary 373 bile acid metabolism and androgenic steroids are connected to sleep duration and SDB phenotype 374 domain.

375

376 Treated as a bipartite network model, we further characterized the connectivity between the 377 metabolites, grouped at the superpathway level, and sleep domains quantified by network properties. 378 The number of connected metabolites is the lowest for energy metabolites and the highest for lipids, 379 which corresponds to the number of connected sleep phenotypes for the two superpathways and the 380 average connection per node (i.e., links per node) (Figure 9). Similar trend can be observed for the mean 381 number of shared metabolites among sleep phenotypes – the number of overlapping metabolites for 382 sleep phenotypes is the highest among lipids and lowest among energy metabolites, which suggests that 383 more lipids are connected to the same sleep phenotype compared to metabolites from other 384 superpathways. The mean number of shared sleep phenotypes among metabolites, however, peaked

385 for carbohydrates and cofactors and vitamins, followed by lipids, suggesting metabolites from the

- former two superpathways are more likely to connected to similar sleep phenotypes than other
- 387 superpathways, despite their low number of total metabolites.

388

- Cluster coefficient, the number of realized links divided by the number of possible links, is the highest among carbohydrates and nucleotides. This pattern indicates a higher degree of overlap in the neighboring nodes among carbohydrates and nucleotides, compared to unnamed metabolites and when combining all metabolites together regardless of superpathways, which may suggest a lower
- 393 degree of diversity in terms of their connectivity patterns.

394

Nestedness of a graph is the property where groups of connected nodes are nested within larger groups of connected nodes. Two versions of nestedness measures were calculated. Both weighted (using the number of sleep domain-superpathway associations) and non-weighted nestedness measures generally agree, and suggest relatively high nestedness among lipids, amino acids, unnamed metabolites as well as combining all metabolites together, and relatively low nestedness among energy, carbohydrates and nucleotides (Supplementary Table S6).

401

Modularity Q is a measure of community structure. Modulatory values are higher when there are more
clusters of connected nodes in a graph. Modularity Q was the highest among energy (Q=0.57) and
xenobiotics (Q=0.57), followed by peptides (Q=0.52), and the lowest among cofactors and vitamins
(Q=0.39) and lipids (Q=0.4), suggesting that among the former three superpathways, there are groups of
metabolites in the superpathway that tend to connect to the same sleep phenotype. Among lipids, and

407 cofactors and vitamins, there are less such "communities" of metabolites with similar sleep domain408 connections.

409

410 Discussion

411

412 In this study we performed single metabolite association analyses for a variety of sleep phenotypes 413 including SDB, insomnia, sleep duration, sleep timing, and heart rate measures during sleep, adjusted 414 for common demographic covariates and BMI, and identified metabolites with statistically significant 415 associations with each sleep phenotype. Taking a network analysis approach, we developed a bipartite 416 network based on the identified associations between metabolites and sleep phenotypes. This approach 417 characterizes the connectivity patterns of metabolites from different metabolite super- and sub-418 pathways, and identifies "neighboring" metabolites and sleep phenotypes that are inter-connected, as 419 well as metabolomic subpathways that may be of interest for further study. 420 421 Many of the metabolites identified in our study as associated with sleep phenotypes have been 422 previously reported to be linked to various sleep phenotypes, usually concurring with our findings. 423 Among the top 10% of connected metabolites with the highest number of associations, regardless of 424 sleep phenotype domain, almost all metabolites were reported in prior publications (Table 3), of which 425 22 were related to sleep. These include some published results from our prior work in HCHS/SOL (i.e., 426 non-independent findings). Glycine, for instance, has shown associations with multiple SDB phenotypes, 427 and was reported to be associated with sleep deprivation (44,45). In a recent study, glycine was found to 428 be depleted in blood among Hispanic/Latino individuals with severe SDB, likely due to microbiome 429 changes in an oxygen-poor environment (46). Four other metabolites – 1-oleoyl-GPE (18:1), 1-(1-enyl-

430	palmitoyl)-GPC (P-16:0)*, pregnenolone sulfate, 5alpha-pregnan-3beta,20alpha-diol monosulfate (2),
431	previously reported to be associated with novel SDB phenotype metrics after dimension reduction in our
432	prior work in HCHS/SOL (43), were here also associated with several SDB phenotypes as well as with
433	phenotypes from domains including insomnia, sleep timing, and heart rate during sleep.
434	
435	Some of the metabolites identified in this study were also reported to be associated with other
436	comorbidities such as cardiovascular, metabolic, and neurodegenerative diseases, potentially
437	connecting sleep to a wide range of chronic adverse health outcomes. For instance, 1-
438	carboxyethylisoleucine and 1-carboxyethylphenylalanine, both associated with sleep duration, SDB,
439	sleep timing and heart rate during sleep, were both reported to be altered in blood among type II
440	diabetes patients (47), while 1-carboxyethylisoleucine, among several other branched-chain amino acid
441	metabolites, was also altered in serum levels among gestational diabetes patients (48). Another amino
442	acid from the top 10% connected metabolites list, 1-carboxyethylvaline, was reported to be associated
443	with hypertension (49). Hexadecanedioate (C16-DC), a dicarboxylate fatty acid, was reported to be
444	associated with blood pressure regulation (50) and neurodegenerative diseases (51). Beta-
445	cryptoxanthin, an antioxidant and pre-vitamin A carotenoid found in fruits and vegetables, was found
446	positively associated with cognition (analysis was not adjusted for sleep traits) in individuals of diverse
447	race/ethnic backgrounds (52). These metabolites suggest some shared biochemical mechanisms
448	between sleep and other chronic adverse health outcomes.

449

Table 3: Top sleep-connected metabolites and their relevant previously-reported associations.					
Metabolite	Super pathway	Sub pathway	Prior publications		
glycine	Amino Acid	Glycine, Serine and Threonine Metabolism	Sleep deprivation (44), OSA (46)		
N-acetylglycine	Amino Acid	Glycine, Serine and Threonine Metabolism	Sleep restriction (53)		
1-carboxyethylisoleucine	Amino Acid	Leucine, Isoleucine and Valine Metabolism	T2DM(47) and GDM (48)		
1-carboxyethylvaline	Amino Acid	Leucine, Isoleucine and Valine Metabolism	HTN (49)		
lysine	Amino Acid	Lysine Metabolism	Insomnia (54), repeated sleep disruption (55)		
1-carboxyethylphenylalanine	Amino Acid	Phenylalanine Metabolism	T2DM (47)		
vanillylmandelate (VMA)	Amino Acid	Tyrosine Metabolism	Sleep deprivation (56)		
pro-hydroxy-pro	Amino Acid	Urea cycle; Arginine and Proline Metabolism	Sleep midpoint (27)		
erythronate*	Carbohydrate	Aminosugar Metabolism	Sleep midpoint and wake time (57)		
1-methylnicotinamide	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism	Sleep restriction (58)		
N1-Methyl-2-pyridone-5- carboxamide	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism	Sleep restriction (58)		
nicotinamide N-oxide	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism	Anti-inflammatory effect (59)		
beta-cryptoxanthin	Cofactors and Vitamins	Vitamin A Metabolism	Sleep duration (60), sleepiness and sleep disturbance (61) cognitive function (52)		
behenoyl dihydrosphingomyelin (d18:0/22:0)*	Lipid	Dihydrosphingomyelins	Physical exercise (62)		
sphingomyelin (d18:0/20:0, d16:0/22:0)*	Lipid	Dihydrosphingomyelins	Blood pressure (63)		
hexadecanedioate (C16-DC)	Lipid	Fatty Acid, Dicarboxylate	Blood pressure regulation (50), neurodegenerative diseases (51)		
1-linoleoyl-GPE (18:2)*	Lipid	Lysophospholipid	Depression (64)		
1-oleoyl-GPE (18:1)	Lipid	Lysophospholipid	SDB (43)		
1-(1-enyl-palmitoyl)-GPC (P- 16:0)*	Lipid	Lysoplasmalogen	SDB (43)		
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2)	Lipid	Phosphatidylethanolamine (PE)	Infant sepsis (65)		
1-stearoyl-2-oleoyl-GPE (18:0/18:1)	Lipid	Phosphatidylethanolamine (PE)	OSA (24)		
pregnenolone sulfate	Lipid	Pregnenolone Steroids	SDB (43), REM sleep (66)		
glycochenodeoxycholate	Lipid	Primary Bile Acid Metabolism	Poor sleep quality (67)		
glycochenodeoxycholate 3- sulfate	Lipid	Primary Bile Acid Metabolism	OSA (29)		

glycocholate	Lipid	Primary Bile Acid Metabolism	OSA (26)
taurochenodeoxycholate	Lipid	Primary Bile Acid Metabolism	OSA (26), sleep midpoint (27)
5alpha-pregnan- 3beta,20alpha-diol monosulfate (2)	Lipid	Progestin Steroids	SDB (43)
glycoursodeoxycholate	Lipid	Secondary Bile Acid Metabolism	Bed time (68)
ursodeoxycholate	Lipid	Secondary Bile Acid Metabolism	OSA intermittent hypoxia/hypercapnia (69)
pentose acid*	Partially Characterized Molecules	Partially Characterized Molecules	REM vs wakefulness (70)
gamma-glutamylisoleucine*	Peptide	Gamma-glutamyl Amino Acid	Sleep midpoint (27), wake time and sleep midpoint (57)
gamma-glutamyltryptophan	Peptide	Gamma-glutamyl Amino Acid	Late-onset sepsis among premature infants (71)
mannonate*	Xenobiotics	Food Component/Plant	Undernutrition (72)

452	When working with complex data such as untargeted metabolomic profiling and multiple phenotypes,
453	effectively summarize data and develop useful insights is challenging (73). Different visualization and
454	analytical approaches have been developed to facilitate this process (74). Here, we applied a systems
455	biological approach – network analysis which has been widely used in gene expression, gene regulation,
456	gene-disease network, and drug-drug interaction studies, on statistical relations among multiple
457	phenotypes and metabolites. This data-driven network approach is different from knowledge-based
458	network construction approaches (75) built on biochemical relations such as KEGG networks (76). Here,
459	the network was built on inferred statistical relations among metabolites and phenotypes, leveraging,
460	for interpretation purposes, well-studied network properties metrics from other fields such as ecology,
461	socioeconomics, neuroscience, drug-disease networks, among others (77–80). One interesting
462	observation is the relatively high nestedness among lipids and amino acids. High nestedness indicates
463	that metabolites from these two superpathways form such a structure that metabolites with fewer
464	connections (referred to as "degree") are more likely to "connect", via their mutual connections with
465	sleep domains, with metabolites with higher degree of connections, rather than with other metabolites

466 with a similar low degree of connectiveness. An intuitive depiction of such network is a "core-periphery" 467 structure, in which a "core" of nodes is connected with other nodes, where a "periphery" of nodes tends 468 to only connect with the nodes in the core. Contextually, among lipids and amino acids associated with 469 sleep phenotypes, higher nestedness, compared to other superpathways, implies that these 470 superpathways are more likely to have a subset of metabolites that play a "key" role forming 471 connections with many, and the same, sleep phenotypes, rather than an evenly distributed network 472 where metabolites form connections with various sleep phenotypes from different domains in a random 473 manner. This is supported by the pattern observed in Figure 8 where subpathways from amino acids and 474 lipids superpathways tend to be placed in the center of the network graph. Metabolites with high 475 connectiveness from these two super-pathways likely have roles in shared biological processes across 476 multiple sleep phenotypes, especially considering 24 out of 37 top 10% connected metabolites are 477 either amino acids or lipids. Modularity metrics, on the other hand, measure how well a network can be 478 partitioned into clusters or compartments in which there are dense connections internally and sparser 479 connections with other clusters (81). Among energy and peptide metabolites associated with sleep 480 phenotypes, relatively higher modularity compared to other superpathways suggests the existence of 481 such subgroups with distinct relationships with sleep phenotypes.

482

HR domain had the highest percentage of metabolite associations of these assessed. HR during sleep reflects activity of the autonomic nervous system, and is influenced by cardiac function, sleep stage (i.e., lowest in deep restorative sleep and highest and most variable in REM sleep and wakefulness during the sleep period), and sleep apnea-related heart rate response (82,83). Notably, both low and elevated heart rate response to SDB events are associated with biomarkers of cardiovascular disease, while elevated heart rate response to SDB events is predictive of incident fatal and non-fatal CVD (84). The finding that HR during sleep associated with hundreds of metabolites, from all superpathways, may

490	reflect the multiple biological mechanisms that underlie this phenotype, as well as support the sleep-
491	related HR as a marker of multiple biologically processes that may be targeted for interventions. Sleep
492	timing also was associated with a relatively high number of metabolite associations, supportive of
493	growing data implicating timing-related behaviors on metabolic outcomes (85), as well as the correlation
494	of sleep timing with other sleep domains (86). In contrast, fewer associations were observed between
495	SDB phenotypes and metabolites. This may be because that SDB measured by traditional metrics such as
496	the AHI may poorly characterize disease that is influenced by multiple mechanistic pathways (87).

497

498 An analytic choice that we made that is worth discussing is missing metabolite data imputation. Here, 499 we imputed missing values of metabolites with no more than 25% missing values. For non-xenobiotic 500 metabolites, we selected the imputation method based on an empirical investigation of the proportion 501 of replicated associations between batches, and the selected method was multiple imputation that 502 included all metabolite and other measures (covariates and lab values) that have strong associations 503 with metabolite levels. It is natural to question whether this may somehow bias results: for example, is it 504 possible that, for instance, using diabetes and BMI (among the rest) to impute metabolite values will 505 lead to metabolite values that are "too reflective" or BMI and diabetes and therefore will somehow 506 generate spurious metabolite associations with sleep measures that are associated with BMI and 507 diabetes? The answer is that this is very unlikely. Generation of metabolite values that are overly similar 508 to BMI or diabetes (in this example) by the predictive mean matching function suggests overfitting to 509 the values of these covariates. Such overfitting will reduce the likelihood of replication of associations in 510 the second batch, rather than increase it. Further, the predictive mean matching has some randomness 511 due to sampling, further limiting overfitting to the variables used in imputation. Finally, it is important to 512 note that the correlation between metabolites and covariates, as with sleep, is an inherent

characteristic of this biological signal (i.e. it is a "feature, not a bug"), as are the metabolite associations
with sleep measures. Therefore, leveraging this characteristic is useful.

515

516 There are a few strengths to this study: we looked at multiple sleep phenotypes simultaneously which 517 provides a unique opportunity for pattern recognition across phenotypes. We also explored the network 518 analysis approach in summarizing the metabolite-sleep phenotypes associations which enabled us to 519 leverage well developed network property metrics from other fields to offer new insights and potentially lead to more hypothesis generation. Additionally, we compared the metabolite-sleep phenotype 520 521 associations in combined sexes and sex-stratified study populations, recognizing more work is needed to 522 further understand the implications of potential differences. Lastly, the atlas created in this study will be 523 a useful resource for the scientific community. This study also has a few limitations. First, our study 524 population is based on the HCHS/SOL cohort, representative of the Hispanic/Latino population in the US. 525 Although it's important to study under-represented populations such as Hispanic/Latino individuals, 526 further studies on other populations are needed to increase the generalizability of the findings. Second, 527 the network analysis conducted in this study is not to make network inference but to summarize the 528 associations results. Third, due to the large breadth of analyses we did not account for medication use in 529 this work. This can influence associations as medications can affect metabolite levels and sleep 530 phenotypes. Similarly, fourth, our primary model for which we summarize the results was not adjusted for comorbidities. In all, one cannot infer mechanisms and directionality of associations from these 531 532 analyses. Fifth, another limitation is that the objective overnight sleep measures did not use EEG, 533 limiting SDB (e.g. we do not have measures of arousals) as well as potential sleep staging measures. 534 Finally, any comparison between the sleep domains used in this analysis is limited by the available sleep 535 phenotypes, their number, and the correlation patterns between them.

5	3	6

537	In summary, we studied the associations between multiple sleep phenotypes from multiple sleep
538	domains and the metabolomic environment in a large population-based cohort study. Using network
539	analysis, we were able to visualize the interconnectedness between multiple sleep phenotypes and
540	associated metabolites simultaneously, which provides an opportunity to glean into connectivity
541	patterns that otherwise might be obscure when presented as individual relationships. We also created a
542	resource for the sleep research community that will facilitate hypothesis generation in future
543	metabolomic studies on sleep health. As sleep is highly affected by the social and built environment, it
544	would be important, in the future, to use metabolomics to glean into the pathways by which the
545	environment impacts sleep.
546	
547 548	Figure legends
547 548 549	Figure legends Figure 1. Study design diagram
547 548 549 550	Figure legends Figure 1. Study design diagram Figure 2. Scatter plot of single metabolite association analysis with sleep phenotypes
547 548 549 550 551	Figure legends Figure 1. Study design diagram Figure 2. Scatter plot of single metabolite association analysis with sleep phenotypes -log10(FDR-p) is based on FDR-adjusted p in which the raw p was derived by accounting for the complex
547 548 549 550 551 552	Figure legends Figure 1. Study design diagram Figure 2. Scatter plot of single metabolite association analysis with sleep phenotypes -log10(FDR-p) is based on FDR-adjusted p in which the raw p was derived by accounting for the complex sampling design-based degrees of freedom, using adjusted standard errors to compute the t-statistic in
547 548 549 550 551 552 553	Figure legends Figure 1. Study design diagram Figure 2. Scatter plot of single metabolite association analysis with sleep phenotypes -log10(FDR-p) is based on FDR-adjusted p in which the raw p was derived by accounting for the complex sampling design-based degrees of freedom, using adjusted standard errors to compute the t-statistic in single metabolite association analysis with each sleep phenotype as dependent variables, while the FDR
547 548 549 550 551 552 553 554	Figure legends Figure 1. Study design diagram Figure 2. Scatter plot of single metabolite association analysis with sleep phenotypes -log10(FDR-p) is based on FDR-adjusted p in which the raw p was derived by accounting for the complex sampling design-based degrees of freedom, using adjusted standard errors to compute the t-statistic in single metabolite association analysis with each sleep phenotype as dependent variables, while the FDR adjustment was based on the Benjamini-Hochberg method to control false discovery rate (FDR) for
547 548 549 550 551 552 553 554 555	Figure legends Figure 1. Study design diagram Figure 2. Scatter plot of single metabolite association analysis with sleep phenotypes -log10(FDR-p) is based on FDR-adjusted p in which the raw p was derived by accounting for the complex sampling design-based degrees of freedom, using adjusted standard errors to compute the t-statistic in single metabolite association analysis with each sleep phenotype as dependent variables, while the FDR adjustment was based on the Benjamini-Hochberg method to control false discovery rate (FDR) for multiple testing among all metabolites in all models for each sleep phenotype. Black horizontal line
547 548 549 550 551 552 553 554 555 556	Figure legends Figure 1. Study design diagram Figure 2. Scatter plot of single metabolite association analysis with sleep phenotypes -log10(FDR-p) is based on FDR-adjusted p in which the raw p was derived by accounting for the complex sampling design-based degrees of freedom, using adjusted standard errors to compute the t-statistic in single metabolite association analysis with each sleep phenotype as dependent variables, while the FDR adjustment was based on the Benjamini-Hochberg method to control false discovery rate (FDR) for multiple testing among all metabolites in all models for each sleep phenotype. Black horizontal line indicates FDR-p=0.05.

558 Figure 3. Number of statistically significant associations between metabolites and sleep phenotypes

559 by domain and sex strata

- 560 Associations between metabolite and sleep phenotype are identified as statistically significant based on
- 561 FDR-p<0.05. The raw *p*-value was derived by accounting for the complex sampling design-based degrees
- 562 of freedom, using adjusted standard errors to compute the t-statistic in single metabolite association
- analysis with each sleep phenotype as dependent variables. The FDR adjustment was based on the
- 564 Benjamini-Hochberg method to control false discovery rate (FDR) for multiple testing among all
- 565 metabolites in all models for each sleep phenotype.

566

567 Figure 4. Number of statistically significant associations between metabolites and sleep phenotypes

568 aggregated by subpathway and sleep phenotype domain

569

570 Figure 5. Percentage of statistically significant associations between metabolites and sleep

571 phenotypes aggregated by superpathway and sleep phenotype domain

572

- 573 Figure 6. Number of significant associations aggregated by sleep phenotype domain among the top
- 574 **10%** connected metabolites with the most statistically significant associations

575

576 Figure 7. Dice coefficient matrix of sleep phenotype domain based on associated metabolites

- 577 Dice coefficient was calculated based on the shared associations with metabolites between any two
- 578 sleep phenotype domain over the total significant associations for both sleep phenotype domains

- 579 combined. A high value (maximum value of 1) indicates complete overlap, while a low value (minimum
- value of 0) indicates no overlap between two sleep phenotype domains.

581 Figure 8. Network based on associations between metabolites and sleep phenotypes aggregated by

582 subpathway and sleep phenotype domain using the Fruchterman-Reingold force-directed algorithm

- 583 Here we present a network of nodes and edges in which each node represents either a sleep phenotype
- 584 domain or a metabolomic subpathway, while each edge represents one or more statistically significant
- associations between two nodes based on the single metabolite association analysis results (FDR-
- 586 corrected p<0.05). The width of the edge (i.e., degree) indicates the number of statistically significant
- associations between two nodes. The placement of nodes is based on connectivity similarity between
- 588 nodes, where similar connectivity is reflected as proximity of nodes.

589

590 Figure 9. Network structural property metrics summarized by superpathway

- 591 Network properties metrics were calculated for the bipartite network based on the significant
- associations between metabolites and sleep phenotypes (FDR-corrected P<0.05). Cluster coefficients is
- 593 the number of realized links divided by the number of possible links
- 594 [https://www.rdocumentation.org/packages/bipartite/versions/2.19/topics/networklevel]. Nestedness
- 595 measures how the interactions of less connected nodes are a subset of the interactions of more
- 596 connected nodes. A value of 0 indicates high nestedness, while a value of 100 indicates "chaos".
- 597 Weighted nestedness considers interaction frequencies of the network, proposed by Galeano et al.(75).
- 598 It ranges between 1 (perfect nestedness) and 0 (perfect chaos). Modularity Q is a measure to quantify
- 599 how well a network can be partitioned into different groups of nodes such that nodes that belong to the
- same group are more likely to be connected than nodes that belong to different groups.

601	Supplementary Figure S1: Study sample selection and pre-processing for the metabolomic analysis.
602	Supplementary Figure S2: Number of statistically significant associations between metabolites and
603	sleep phenotypes aggregated by subpathway and sleep phenotype domain stratified by sex.
604 605	Data availability
606	HCHS/SOL data are available through application to the data base of genotypes and phenotypes (dbGaP)
607	accession phs000810. HCHS/SOL metabolomics data are available via data use agreement with the
608	HCHS/SOL Data Coordinating Center (DCC) at the University of North Carolina at Chapel Hill, see
609	collaborators website: https://sites.cscc.unc.edu/hchs/. The metabolite association data generated in
610	this study are provided in a shiny app https://bws-bidmc.shinyapps.io/20240410_for_shinyappsio/.
611	
612	Code availability
613	The code used in this work has been deposited in the public repository
614	https://github.com/yzhang104/HCHS_SOL_Sleep_Metabolomics_Atlas.git.
615	
616 617	Ethics statement The HCHS/SOL was approved by the institutional review boards (IRBs) at each field center, where all
618	participants gave written informed consent, and by the Non-Biomedical IRB at the University of North
619	Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. All IRBs approving the HCHS/SOL
620	study are: Non-Biomedical IRB at the University of North Carolina at Chapel Hill. Chapel Hill, NC; Einstein
621	IRB at the Albert Einstein College of Medicine of Yeshiva University. Bronx, NY; IRB at Office for the
622	Protection of Research Subjects (OPRS), University of Illinois at Chicago. Chicago, IL; Human Subject
623	Research Office, University of Miami. Miami, FL; Institutional Review Board of San Diego State

624	University, San Diego, CA. All methods and analyses of HCHS/ SOL participants' materials and data were
625	carried out in accordance with human subject research guidelines and regulations. This work was
626	approved by the Mass General Brigham IRB and by the Beth Israel Deaconess Medical Center Committee
627	on Clinical Investigations.
628	
629 630	Declaration of interests Dr. Redline discloses consulting relationships with Eli Lilly Inc. Additionally, Dr. Redline serves as an
631	unpaid member of the Apnimed Scientific Advisory Board, as an unpaid board member for the Alliance
632	for Sleep Apnoea Partners, and has received loaned equipment for a multi-site study: oxygen
633	concentrators from Philips Respironics and polysomnography equipment from Nox Medical.
634	
635	
636	Acknowledgements
637	The authors thank the staff and participants of HCHS/SOL for their important contributions.
638	Investigators website - http://www.cscc.unc.edu/hchs/. This work was supported by National Heart
639	Lung and Blood Institute (NHLBI) grants R01HL161012 to TS, R35HL135818 to SR, and National Institute
640	on Aging grant R01AG80598 to TS. Support for metabolomics data was graciously provided by the JLH
641	Foundation (Houston, Texas) and by NHLBI grant R01HL141824. The Hispanic Community Health
642	Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung,
643	and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I / N01-HC-65233),
644	University of Miami (HHSN268201300004I / N01-HC-65234), Albert Einstein College of Medicine
645	(HHSN268201300002I / N01-HC-65235), University of Illinois at Chicago (HHSN268201300003I / N01-
646	HC-65236 Northwestern Univ), and San Diego State University (HHSN268201300005I / N01-HC-65237).

647	The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds				
648	to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on				
649	Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research,				
650	National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological				
651	Disorders and Stroke, NIH Institution-Office of Dietary Supplements.				
652					
653	Contributions of the authors				
654	Ying Z	performed association analyses, network analyses, and data visualization. BWS developed the			
655	R/shiny app for visualization of results from single metabolite association analysis. Yu Z performed data				
656	imputation. DAW provided code for modeling circular sleep phenotypes. BY, QQ, and EB designed and				
657	establi	shed the metabolomics ancillary studies. MA, LA-S, MD, RK, and JC participated in HCHS/SOL			
658	study design, recruitment, and operations. Ying Z and TS drafted the manuscript. BWS, Yu Z, DAW, BY,				
659	QQ, MA, LA-S, EB, MD, RK, JC, and SR critically reviewed and approved the manuscript. TS supervised the				
660	work.				
661 662	References				
663					
664					
665 666 667	1.	Chattu VK, Manzar MD, Kumary S, Burman D, Spence DW, Pandi-Perumal SR. The global problem of insufficient sleep and its serious public health implications. Healthcare (Basel). 2018 Dec 20;7(1).			
668 669	2.	Worley SL. The extraordinary importance of sleep: the detrimental effects of inadequate sleep on health and public safety drive an explosion of sleep research. P T. 2018 Dec;43(12):758–63.			
670 671 672	3. Ramar K, Malhotra RK, Carden KA, Martin JL, Abbasi-Feinberg F, Aurora RN, et al. Sleep is essential to health: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2021 Oct 1;17(10):2115–9.				

673 4. loachimescu OC. From seven sweethearts to life begins at eight thirty: A journey from life's 674 simple 7 to life's essential 8 and beyond. J Am Heart Assoc. 2022 Nov;11(21):e027658. 675 5. Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014 Jan 1;37(1):9–17. 676 6. Chung J, Goodman M, Huang T, Wallace ML, Lutsey PL, Chen JT, et al. Multi-dimensional sleep 677 and mortality: The Multi-Ethnic Study of Atherosclerosis. Sleep. 2023 Sep 8;46(9). 678 7. Lee S, Mu CX, Wallace ML, Andel R, Almeida DM, Buxton OM, et al. Multidimensional sleep 679 health problems across middle and older adulthood predict early mortality. J Gerontol A Biol Sci 680 Med Sci. 2024 Mar 1;79(3). 681 8. Lee S, Mu CX, Wallace ML, Andel R, Almeida DM, Buxton OM, et al. Sleep health composites are 682 associated with the risk of heart disease across sex and race. Sci Rep. 2022 Feb 7;12(1):2023. 683 9. Sofer T, Kurniansyah N, Murray M, Ho Y-L, Abner E, Esko T, et al. Genome-wide association study of obstructive sleep apnoea in the Million Veteran Program uncovers genetic heterogeneity by 684 685 sex. EBioMedicine. 2023 Apr;90:104536. 686 10. Madrid-Valero JJ, Sánchez-Romera JF, Martínez-Selva JM, Ordoñana JR. Phenotypic, genetic and 687 environmental architecture of the components of sleep quality. Behav Genet. 2022 Sep;52(4– 5):236-45. 688 689 11. Wang H, Lane JM, Jones SE, Dashti HS, Ollila HM, Wood AR, et al. Genome-wide association 690 analysis of self-reported daytime sleepiness identifies 42 loci that suggest biological subtypes. 691 Nat Commun. 2019 Aug 13;10(1):3503. 692 12. Sweetman A, Lack L, McEvoy RD, Smith S, Eckert DJ, Osman A, et al. Bi-directional relationships 693 between co-morbid insomnia and sleep apnea (COMISA). Sleep Med Rev. 2021 Dec;60:101519. 694 13. Amatoury J, Azarbarzin A, Younes M, Jordan AS, Wellman A, Eckert DJ. Arousal intensity is a 695 distinct pathophysiological trait in obstructive sleep apnea. Sleep. 2016 Dec 1:39(12):2091–100. 696 14. Keenan BT, Kim J, Singh B, Bittencourt L, Chen N-H, Cistulli PA, et al. Recognizable clinical 697 subtypes of obstructive sleep apnea across international sleep centers: a cluster analysis. Sleep. 698 2018 Mar 1;41(3). 699 15. Zinchuk AV, Jeon S, Koo BB, Yan X, Bravata DM, Qin L, et al. Polysomnographic phenotypes and 700 their cardiovascular implications in obstructive sleep apnoea. Thorax. 2018 May;73(5):472–80. 701 16. Zhang L, Wei T-T, Li Y, Li J, Fan Y, Huang F-Q, et al. Functional Metabolomics Characterizes a Key 702 Role for N-Acetylneuraminic Acid in Coronary Artery Diseases. Circulation. 2018 Mar 703 27;137(13):1374-90. 704 17. Buergel T, Steinfeldt J, Ruyoga G, Pietzner M, Bizzarri D, Vojinovic D, et al. Metabolomic profiles 705 predict individual multidisease outcomes. Nat Med. 2022 Nov;28(11):2309–20. 706 18. Nikolic SB, Sharman JE, Adams MJ, Edwards LM. Metabolomics in hypertension. J Hypertens. 707 2014 Jun;32(6):1159-69.

- Griffin JL, Atherton H, Shockcor J, Atzori L. Metabolomics as a tool for cardiac research. Nat Rev
 Cardiol. 2011 Sep 20;8(11):630–43.
- Yu B, Flexeder C, McGarrah RW, Wyss A, Morrison AC, North KE, et al. Metabolomics identifies
 novel blood biomarkers of pulmonary function and COPD in the general population. Metabolites.
 2019 Apr 1;9(4).
- Depner CM, Cogswell DT, Bisesi PJ, Markwald RR, Cruickshank-Quinn C, Quinn K, et al. Developing
 preliminary blood metabolomics-based biomarkers of insufficient sleep in humans. Sleep. 2020
 Jul 13;43(7).
- He S, Granot-Hershkovitz E, Zhang Y, Bressler J, Tarraf W, Yu B, et al. Blood metabolites predicting
 mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging
 (HCHS/SOL). Alzheimers Dement (Amst). 2022 Feb 23;14(1):e12259.
- Fritz J, Huang T, Depner CM, Zeleznik OA, Cespedes Feliciano EM, Li W, et al. Sleep duration,
 plasma metabolites, and obesity and diabetes: a metabolome-wide association study in US
 women. Sleep. 2023 Jan 11;46(1).
- Zhang Y, Ngo D, Yu B, Shah NA, Chen H, Ramos AR, et al. Development and validation of a metabolite index for obstructive sleep apnea across race/ethnicities. Sci Rep. 2022 Dec 16;12(1):21805.
- Lin BM, Zhang Y, Yu B, Boerwinkle E, Thygarajan B, Yunes M, et al. Metabolome-wide association
 study of estimated glomerular filtration rates in Hispanics. Kidney Int. 2022 Jan;101(1):144–51.
- Pinilla L, Benítez ID, Santamaria-Martos F, Targa A, Moncusí-Moix A, Dalmases M, et al. Plasma
 profiling reveals a blood-based metabolic fingerprint of obstructive sleep apnea. Biomed
 Pharmacother. 2022 Jan;145:112425.
- Xiao Q, Derkach A, Moore SC, Zheng W, Shu X-O, Gu F, et al. Habitual Sleep and human plasma
 metabolomics. Metabolomics. 2017 May;13(5).
- 732 28. Humer E, Pieh C, Brandmayr G. Metabolomics in sleep, insomnia and sleep apnea. Int J Mol Sci.
 733 2020 Sep 30;21(19).
- Xu H, Zheng X, Qian Y, Guan J, Yi H, Zou J, et al. Metabolomics profiling for obstructive sleep
 apnea and simple snorers. Sci Rep. 2016 Aug 2;6:30958.
- 30. Lebkuchen A, Carvalho VM, Venturini G, Salgueiro JS, Freitas LS, Dellavance A, et al. Metabolomic
 and lipidomic profile in men with obstructive sleep apnoea: implications for diagnosis and
 biomarkers of cardiovascular risk. Sci Rep. 2018 Jul 26;8(1):11270.
- Mohit, Tomar MS, Sharma D, Nandan S, Pateriya A, Shrivastava A, et al. Emerging role of
 metabolomics for biomarker discovery in obstructive sleep apnea. Sleep Breath. 2023
 Aug;27(4):1247–54.
- 32. Lavange LM, Kalsbeek WD, Sorlie PD, Avilés-Santa LM, Kaplan RC, Barnhart J, et al. Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos. Ann Epidemiol.
 2010 Aug;20(8):642–9.

33. Sorlie PD, Avilés-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML, Giachello AL, et al.
Design and implementation of the Hispanic Community Health Study/Study of Latinos. Ann
Epidemiol. 2010 Aug;20(8):629–41.

- Pirzada A, Cai J, Heiss G, Sotres-Alvarez D, Gallo LC, Youngblood ME, et al. Evolving science on
 cardiovascular disease among hispanic/latino adults: JACC international. J Am Coll Cardiol. 2023
 Apr 18;81(15):1505–20.
- 751 35. Redline S, Sotres-Alvarez D, Loredo J, Hall M, Patel SR, Ramos A, et al. Sleep-disordered breathing
 752 in Hispanic/Latino individuals of diverse backgrounds. The Hispanic Community Health
 753 Study/Study of Latinos. Am J Respir Crit Care Med. 2014 Feb 1;189(3):335–44.
- 36. Gonzalez S, Strizich G, Isasi CR, Hua S, Comas B, Sofer T, et al. Consent for Use of Genetic Data
 among US Hispanics/Latinos: Results from the Hispanic Community Health Study/ Study of
 Latinos. Ethn Dis. 2021 Oct 21;31(4):547–58.
- Kim S, SenGupta A. Regressions involving circular variables: an overview. In: Chattopadhyay AK,
 Chattopadhyay G, editors. Statistics and its applications: platinum jubilee conference, kolkata,
 india, december 2016. Singapore: Springer Singapore; 2018. p. 25–33.
- 760 38. Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc. 1996 Jun;91(434):473.
- 39. Liu Y, Chen S, Li Z, Morrison AC, Boerwinkle E, Lin X. ACAT: A Fast and Powerful p Value
 Combination Method for Rare-Variant Analysis in Sequencing Studies. Am J Hum Genet. 2019
 Mar 7;104(3):410–21.
- 40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach
 to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological). 1995
 Jan;57(1):289–300.
- 41. Sørensen T, Sørensen T, Biering-Sørensen T, Sørensen T, Sorensen JT. A method of establishing
 group of equal amplitude in plant sociobiology based on similarity of species content and its
 application to analyses of the vegetation on Danish commons. 1948.
- Fruchterman TMJ, Reingold EM. Graph drawing by force-directed placement. Softw: Pract Exper.
 1991 Nov;21(11):1129–64.
- 43. Zhang Y, Yu B, Qi Q, Azarbarzin A, Chen H, Shah NA, et al. Metabolomic profiles of sleepdisordered breathing are associated with hypertension and diabetes mellitus development. Nat
 Commun. 2024 Feb 28;15(1):1845.
- 44. Gou X-J, Cen F, Fan Z-Q, Xu Y, Shen H-Y, Zhou M-M. Serum and brain metabolomic variations
 reveal perturbation of sleep deprivation on rats and ameliorate effect of total ginsenoside
 treatment. Int J Genomics. 2017 Aug 16;2017:5179271.
- 45. Ma W-N, Zhou M-M, Gou X-J, Zhao L, Cen F, Xu Y, et al. Urinary Metabolomic Study of
 Chlorogenic Acid in a Rat Model of Chronic Sleep Deprivation Using Gas Chromatography-Mass
 Spectrometry. Int J Genomics. 2018 Feb 11;2018:1361402.

- 46. Elgart M, Zhang Y, Zhang Y, Yu B, Kim Y, Zee PC, et al. Anaerobic pathogens associated with OSA
 may contribute to pathophysiology via amino-acid depletion. EBioMedicine. 2023
 Dec;98:104891.
- 47. Liu Y, Gan L, Zhao B, Yu K, Wang Y, Männistö S, et al. Untargeted metabolomic profiling identifies
 serum metabolites associated with type 2 diabetes in a cross-sectional study of the AlphaTocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Am J Physiol Endocrinol Metab.
 2023 Feb 1;324(2):E167–75.
- 48. Harville EW, Bazzano L, Qi L, He J, Dorans K, Perng W, et al. Branched-chain amino acids, history
 of gestational diabetes, and breastfeeding: The Bogalusa Heart Study. Nutr Metab Cardiovasc Dis.
 2020 Oct 30;30(11):2077–84.
- 49. Shi M, He J, Li C, Lu X, He WJ, Cao J, et al. Metabolomics study of blood pressure salt-sensitivity
 and hypertension. Nutr Metab Cardiovasc Dis. 2022 Jul;32(7):1681–92.
- Menni C, Graham D, Kastenmüller G, Alharbi NHJ, Alsanosi SM, McBride M, et al. Metabolomic
 identification of a novel pathway of blood pressure regulation involving hexadecanedioate.
 Hypertension. 2015 Aug;66(2):422–9.
- 51. Chen H, Qiao J, Wang T, Shao Z, Huang S, Zeng P. Assessing causal relationship between human
 blood metabolites and five neurodegenerative diseases with GWAS summary statistics. Front
 Neurosci. 2021 Dec 9;15:680104.
- 52. Granot-Hershkovitz E, He S, Bressler J, Yu B, Tarraf W, Rebholz CM, et al. Plasma metabolites
 associated with cognitive function across race/ethnicities affirming the importance of healthy
 nutrition. Alzheimers Dement. 2023 Apr;19(4):1331–42.
- 80253.Bell LN, Kilkus JM, Booth JN, Bromley LE, Imperial JG, Penev PD. Effects of sleep restriction on the803human plasma metabolome. Physiol Behav. 2013 Oct 2;122:25–31.
- S4. Gehrman P, Sengupta A, Harders E, Ubeydullah E, Pack AI, Weljie A. Altered diurnal states in
 insomnia reflect peripheral hyperarousal and metabolic desynchrony: a preliminary study. Sleep.
 2018 May 1;41(5).
- 807 55. Bowers SJ, Vargas F, González A, He S, Jiang P, Dorrestein PC, et al. Repeated sleep disruption in
 808 mice leads to persistent shifts in the fecal microbiome and metabolome. PLoS ONE. 2020 Feb
 809 20;15(2):e0229001.
- 810 56. Müller HU, Riemann D, Berger M, Müller WE. The influence of total sleep deprivation on urinary
 811 excretion of catecholamine metabolites in major depression. Acta Psychiatr Scand. 1993
 812 Jul;88(1):16–20.
- 57. Gordon-Dseagu VLZ, Derkach A, Xiao Q, Williams I, Sampson J, Stolzenberg-Solomon RZ. The
 association of sleep with metabolic pathways and metabolites: evidence from the Dietary
 Approaches to Stop Hypertension (DASH)-sodium feeding study. Metabolomics. 2019 Mar
 16;15(4):48.

- Sengupta A, Rhoades SD, Kim EJ, Nayak S, Grant GR, Meerlo P, et al. Sleep restriction induced
 energy, methylation and lipogenesis metabolic switches in rat liver. Int J Biochem Cell Biol. 2017
 Dec;93:129–35.
- Song X, Cao W, Wang Z, Li F, Xiao J, Zeng Q, et al. Nicotinamide n-Oxide Attenuates HSV-1 Induced Microglial Inflammation through Sirtuin-1/NF-κB Signaling. Int J Mol Sci. 2022 Dec
 16;23(24).
- 82360.Deng M-G, Liu F, Wang K, Liang Y, Nie J-Q, Liu J. Relationship between dietary carotenoid intake824and sleep duration in American adults: a population-based study. Nutr J. 2023 Dec 8;22(1):68.
- 825 61. Beydoun MA, Gamaldo AA, Canas JA, Beydoun HA, Shah MT, McNeely JM, et al. Serum
 826 nutritional biomarkers and their associations with sleep among US adults in recent national
 827 surveys. PLoS ONE. 2014 Aug 19;9(8):e103490.
- 62. Gaitán JM, Moon HY, Stremlau M, Dubal DB, Cook DB, Okonkwo OC, et al. Effects of Aerobic
 Exercise Training on Systemic Biomarkers and Cognition in Late Middle-Aged Adults at Risk for
 Alzheimer's Disease. Front Endocrinol (Lausanne). 2021 May 20;12:660181.
- 63. He WJ, Li C, Mi X, Shi M, Gu X, Bazzano LA, et al. An untargeted metabolomics study of blood
 pressure: findings from the Bogalusa Heart Study. J Hypertens. 2020 Jul;38(7):1302–11.
- Bansen R, Milaneschi Y, Schranner D, Kastenmuller G, Arnold M, Han X, et al. The MetabolomeWide Signature of Major Depressive Disorder. Res Sq. 2023 Sep 21;
- 835 65. Wang L, Cha X, Zhang Z, Qian J. Discrimination of serum metabolomics profiles in infants with
 836 sepsis, based on liquid chromatography-mass spectrometer. BMC Infect Dis. 2023 Jan
 837 23;23(1):46.
- Barnaudéry M, Bouyer JJ, Pallarés M, Le Moal M, Mayo W. The promnesic neurosteroid
 pregnenolone sulfate increases paradoxical sleep in rats. Brain Res. 1999 Feb 13;818(2):492–8.
- Huang T, Zeleznik OA, Poole EM, Clish CB, Deik AA, Scott JM, et al. Habitual sleep quality, plasma
 metabolites and risk of coronary heart disease in post-menopausal women. Int J Epidemiol. 2019
 Aug 1;48(4):1262–74.
- Kiang X, Chen J, Zhu M, Gao H, Liu X, Wang Q. Multiomics Revealed the Multi-Dimensional Effects
 of Late Sleep on Gut Microbiota and Metabolites in Children in Northwest China. Nutrients. 2023
 Oct 10;15(20).
- 846 69. Xue J, Allaband C, Zhou D, Poulsen O, Martino C, Jiang L, et al. Influence of intermittent
 847 hypoxia/hypercapnia on atherosclerosis, gut microbiome, and metabolome. Front Physiol. 2021
 848 Apr 8;12:663950.
- 84970.Nowak N, Gaisl T, Miladinovic D, Marcinkevics R, Osswald M, Bauer S, et al. Rapid and reversible850control of human metabolism by individual sleep states. Cell Rep. 2021 Oct 26;37(4):109903.
- Liu J, Zhang L, Li D, Yu X, Gao Y, Zhou Y. Intestinal metabolomics in premature infants with late onset sepsis. Sci Rep. 2024 Feb 26;14(1):4659.

Preidis GA, Keaton MA, Campeau PM, Bessard BC, Conner ME, Hotez PJ. The undernourished
neonatal mouse metabolome reveals evidence of liver and biliary dysfunction, inflammation, and
oxidative stress. J Nutr. 2014 Mar;144(3):273–81.

- 856 73. Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted Metabolomics
 857 Strategies-Challenges and Emerging Directions. J Am Soc Mass Spectrom. 2016 Dec;27(12):1897–
 858 905.
- Alonso A, Marsal S, Julià A. Analytical methods in untargeted metabolomics: state of the art in
 2015. Front Bioeng Biotechnol. 2015 Mar 5;3:23.
- 861 75. Galeano J, Pastor JM, Iriondo JM. Weighted-Interaction Nestedness Estimator (WINE): A new
 862 estimator to calculate over frequency matrices. Environmental Modelling & Software. 2009
 863 Nov;24(11):1342–6.
- Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000
 Jan 1;28(1):27–30.
- VIrich W, Almeida-Neto M, Gotelli NJ. A consumer's guide to nestedness analysis. Oikos. 2009
 Jan;118(1):3–17.
- König MD, Tessone CJ, Zenou Y. Nestedness in networks: A theoretical model and some applications. Theoretical Economics. 2014 Sep;9(3):695–752.
- 870 79. Centeno EGZ, Moreni G, Vriend C, Douw L, Santos FAN. A hands-on tutorial on network and
 871 topological neuroscience. Brain Struct Funct. 2022 Apr;227(3):741–62.
- 872 80. Rintala TJ, Ghosh A, Fortino V. Network approaches for modeling the effect of drugs and
 873 diseases. Brief Bioinformatics. 2022 Jul 18;23(4).
- 874 81. Newman MEJ, Girvan M. Finding and evaluating community structure in networks. Phys Rev E
 875 Stat Nonlin Soft Matter Phys. 2004 Feb 26;69(2 Pt 2):026113.
- 876 82. Aldredge JL, Welch AJ. Variations of heart rate during sleep as a function of the sleep cycle.
 877 Electroencephalogr Clin Neurophysiol. 1973 Aug;35(2):193–8.
- 878 83. Yang C-K, Jordan AS, White DP, Winkelman JW. Heart rate response to respiratory events with or
 879 without leg movements. Sleep. 2006 Apr;29(4):553–6.
- 880 84. Azarbarzin A, Sands SA, Younes M, Taranto-Montemurro L, Sofer T, Vena D, et al. The Sleep
 881 Apnea-Specific Pulse-Rate Response Predicts Cardiovascular Morbidity and Mortality. Am J Respir
 882 Crit Care Med. 2021 Jun 15;203(12):1546–55.
- 883 85. Duffy JF, Abbott SM, Burgess HJ, Crowley SJ, Emens JS, Epstein LJ, et al. Workshop report.
 884 Circadian rhythm sleep-wake disorders: gaps and opportunities. Sleep. 2021 May 14;44(5).
- 885
 86. Chung J, Goodman M, Huang T, Bertisch S, Redline S. Multidimensional sleep health in a diverse, aging adult cohort: Concepts, advances, and implications for research and intervention. Sleep
 887 Health. 2021 Dec;7(6):699–707.

888 87. Redline S, Azarbarzin A, Peker Y. Obstructive sleep apnoea heterogeneity and cardiovascular
889 disease. Nat Rev Cardiol. 2023 Aug;20(8):560–73.

Figure 1. Study design diagram





1 Figure 2. Scatter plot of single metabolite association analysis with sleep phenotypes



Figure 4. Number of statistically significant associations between metabolites and sleep phenotypes aggregated by subpathway and sleep phenotype domain



Figure 5. Percentage of statistically significant associations between metabolites and sleep phenotypes aggregated by superpathway and sleep phenotype domain

	Xenobiotics -	5.2%	14.9%	2.2%	1.8%	6.5%
Super Pathway	Unnamed -	8.0%	16.2%	2.2%	1.4%	10.9%
	Peptide -	6.9%	24.0%	1.7%	1.3%	13.7%
	Partially Characterized Molecules-	0.0%	13.9%	0.6%	0.4%	15.9%
	Nucleotide -	14.4%	11.0%	0.9%	0.3%	9.1%
	Lipid-	2.9%	23.0%	3.2%	3.2%	17.3%
	Energy-	7.5%	12.5%	0.0%	5.8%	3.6%
	Cofactors and Vitamins-	10.8%	28.9%	6.4%	1.3%	22.0%
	Carbohydrate -	10.8%	40.4%	4.3%	5.6%	12.1%
	Amino Acid-	6.5%	24.7%	2.7%	2.2%	12.0%
		Duration	HR Sleep	Insomnia Trait Cate	SDB egory	Timing
	Percentage Significant (%)					
0 10 20 30 4				30 40		

Figure 6. Number of significant associations aggregated by sleep phenotype domain among the top 10% connected metabolites with the most statistically significant associations



Metabolites



Figure 7. Dice coefficient matrix of sleep phenotype domain based on associated metabolites

Figure 8. Network based on associations between metabolites and sleep phenotypes aggregated by subpathway and sleep phenotype domain using the Fruchterman-Reingold force-directed algorithm





1 Figure 9. Network structural property metrics summarized by superpathway